Targeting non-coding RNAs for the treatment of retinal diseases

Maintaining visual function is key to establishing improved longevity. However, the numbers of patients with diseases of the retina, the most important tissue for vision and the key to age-related blindness, are not declining due to the increase in the number of aging subjects worldwide and the tech...

Full description

Bibliographic Details
Main Authors: Juhyun Song, Young-Kook Kim
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253121000664
id doaj-d9b1e49f1b3a4101bc0d3dbcfa786a4c
record_format Article
spelling doaj-d9b1e49f1b3a4101bc0d3dbcfa786a4c2021-06-05T06:08:18ZengElsevierMolecular Therapy: Nucleic Acids2162-25312021-06-0124284293Targeting non-coding RNAs for the treatment of retinal diseasesJuhyun Song0Young-Kook Kim1Department of Anatomy, Chonnam National University Medical School, Hwasun 58128, Jeollanam-do, Republic of KoreaDepartment of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Jeollanam-do, Republic of Korea; Corresponding author: Young-Kook Kim, PhD, Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Jeollanam-do, Republic of Korea.Maintaining visual function is key to establishing improved longevity. However, the numbers of patients with diseases of the retina, the most important tissue for vision and the key to age-related blindness, are not declining due to the increase in the number of aging subjects worldwide and the technological advances in the delivery of premature infants. The primary treatment option for retinal diseases is still surgical intervention and includes laser or photocoagulation, which are associated with various complications and side effects. Many aspects of the pathogenesis of these retinal diseases are still unknown, thereby impeding drug discovery. This has led to an increase in the number of studies focused on the underlying pathogenic mechanisms of retinal diseases. Growing evidence suggests that non-coding RNAs play critical roles in the pathogenesis of retinal diseases. Herein, we have summarized the known functional roles of non-coding RNAs, emphasizing their contribution to the underlying pathogenesis of retinal diseases. In addition, we discuss the modulation of non-coding RNAs as potential therapeutics and the methods to control the non-coding RNAs for the treatment. We expect that targeting non-coding RNAs could be crucial for developing novel therapeutics for progressive diseases including diseases of the retina.http://www.sciencedirect.com/science/article/pii/S2162253121000664non-coding RNAretinopathy of prematurityage-related macular degenerationdiabetic retinopathyRNA therapy
collection DOAJ
language English
format Article
sources DOAJ
author Juhyun Song
Young-Kook Kim
spellingShingle Juhyun Song
Young-Kook Kim
Targeting non-coding RNAs for the treatment of retinal diseases
Molecular Therapy: Nucleic Acids
non-coding RNA
retinopathy of prematurity
age-related macular degeneration
diabetic retinopathy
RNA therapy
author_facet Juhyun Song
Young-Kook Kim
author_sort Juhyun Song
title Targeting non-coding RNAs for the treatment of retinal diseases
title_short Targeting non-coding RNAs for the treatment of retinal diseases
title_full Targeting non-coding RNAs for the treatment of retinal diseases
title_fullStr Targeting non-coding RNAs for the treatment of retinal diseases
title_full_unstemmed Targeting non-coding RNAs for the treatment of retinal diseases
title_sort targeting non-coding rnas for the treatment of retinal diseases
publisher Elsevier
series Molecular Therapy: Nucleic Acids
issn 2162-2531
publishDate 2021-06-01
description Maintaining visual function is key to establishing improved longevity. However, the numbers of patients with diseases of the retina, the most important tissue for vision and the key to age-related blindness, are not declining due to the increase in the number of aging subjects worldwide and the technological advances in the delivery of premature infants. The primary treatment option for retinal diseases is still surgical intervention and includes laser or photocoagulation, which are associated with various complications and side effects. Many aspects of the pathogenesis of these retinal diseases are still unknown, thereby impeding drug discovery. This has led to an increase in the number of studies focused on the underlying pathogenic mechanisms of retinal diseases. Growing evidence suggests that non-coding RNAs play critical roles in the pathogenesis of retinal diseases. Herein, we have summarized the known functional roles of non-coding RNAs, emphasizing their contribution to the underlying pathogenesis of retinal diseases. In addition, we discuss the modulation of non-coding RNAs as potential therapeutics and the methods to control the non-coding RNAs for the treatment. We expect that targeting non-coding RNAs could be crucial for developing novel therapeutics for progressive diseases including diseases of the retina.
topic non-coding RNA
retinopathy of prematurity
age-related macular degeneration
diabetic retinopathy
RNA therapy
url http://www.sciencedirect.com/science/article/pii/S2162253121000664
work_keys_str_mv AT juhyunsong targetingnoncodingrnasforthetreatmentofretinaldiseases
AT youngkookkim targetingnoncodingrnasforthetreatmentofretinaldiseases
_version_ 1721396768626704384